LEXAGNE HOLDINGS WKN: A2ATW9 ISIN: CA52886L1031 Kürzel: 5XS2 Forum: Aktien Thema: Hauptdiskussion

Das Teil scheint mir ja ein wundergerät zu sein, falls alles stimmt und der lx wirklich alles erkennt und mit der Genauigkeit ist das hier ne Firma die uns reich macht.

Wenn’s denn alles so stimmt yep

http://www.globenewswire.com/news-release/2019/09/05/1911697/0/en/LexaGene-Reports-on-Beta-Results-from-Cannabis-Focused-Testing-Laboratory.html

Leute! Ist das eine geile Message auf lange Sicht oder ist das eine geile Message! :-)

Mal schauen

Endlich wieder mal grüne Vorzeichen beim Kurs.Plus 5 %. Wenn ab nächstem Monat die ersten Verkäufe getätigt werden,sollten noch mehrere grüne Tage kommen.

Platos! Bist du bei 1 Euro hier rein? Wie ist deinEK?

?

Geld verbrannt wie immer Bull Investor 😅✌🛸

Geld verbrenner 🤔

https://www.newsfilecorp.com/release/47057

aktie fällt trotz guter news.....

Läuft!

LexaGene to Place Beta Unit in Human Clinical Diagnostics Laboratory LexaGene to Place Beta Unit in Human Clinical Diagnostics Laboratory Assurance Scientific Laboratories to explore open-access use for antimicrobial resistance research BEVERLY, Mass. – August 8, 2019 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has an agreement to place a beta prototype with Assurance Scientific Laboratories (ASL) in Vestavia, Alabama in August 2019. ASL is a certified reference laboratory specializing in providing clinical testing results to physicians nationwide. ASL currently processes over 300 urine samples per week for human urinary tract infections – plus hundreds of other sample types. The beta test will focus on testing urine samples to detect the presence of pathogens causing urinary tract infections while simultaneously screening these samples for genetic markers for antimicrobial resistance. ASL has expertise in developing and testing for antimicrobial resistance genes using PCR-based tests. Antimicrobial resistance – the resistance of bacteria, fungus, and viruses to drugs – is a worldwide problem that could cause 10 million deaths each year by 2050.1 Dr. Nathan Walsh, LexaGene’s VP of Applications and Bio-Informatics states, “During this beta test period, ASL will take advantage of the open-access feature of LexaGene’s LX technology to compare our tests to their tests for pathogen identification and antimicrobial resistance characterization. The research data generated will help clinical laboratories better assess the available tools to aid in the diagnosis and treatment of human urinary tract infections.” At ASL, Mary Beth Minyard, Director of Microbiology, and Dr. Greer Massey, Director of Molecular Diagnostics, will lead the project. “We are always looking for new technology to help us streamline sample processing and analysis. We are excited to evaluate LexaGene’s LX technology, especially for its integrated sample extraction, test assembly, and analysis which has the potential to expedite sample processing in the lab, lower costs and minimize errors,” states Massey. Dr. Jack Regan, CEO and Founder of LexaGene states, “Our open-access technology differentiates us from other automated molecular testing technologies. This collaborative effort with ASL, a reference laboratory that processes human samples for clinical diagnostic testing, is a perfect example of a laboratory taking advantage of the open-access feature to test the performance of their own assays on our fully automated analyzer. We are excited to have this opportunity to demonstrate the instrument’s capabilities, and how it may someday be used for human clinical diagnostics.”

Bis der Schuppen hier abläuft dauert es auch noch, die Jungs machen hier aufjedenfall hervorragende Arbeit

ruhig geworden hier.